Bay Area firms lead revolution in cancer care
June 29th, 2007
Genentech has developed three of the most promising cancer drugs — Herceptin, Rituxan for non-Hodgkin’s lymphoma and Avastin for non-small-cell lung cancer and colorectal cancer. Another key cancer drug is Novartis’ Gleevec for chronic myeloid leukemia.